Clinical Efficacy of Fidarestat, a Novel Aldose Reductase Inhibitor, for Diabetic Peripheral Neuropathy: A 52-Week Multicenter Placebo-Controlled Double-Blind Parallel Group Study
Diabetes Care - United States
doi 10.2337/diacare.24.10.1776
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2001
Authors
Publisher
American Diabetes Association